Figures & data
Figure 1. The structure of vincristine.
Figure 2. The development of liposomal vincristine.
Figure 3. The antitumor effect of vincristine formulations in SCID mice bearing A431 tumors. The control group (▪) received no treatment and vincristine formulations (vincristine solution (□), DSPC/Chol (○) or SM/Chol (•) liposomal vincristine) were intravenously injected at a dose of 2.0 vincristine mg/kg. Reprinted by permission from Macmillan Publishers Ltd: British Journal of Cancer, 72(4), Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD, Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumor models, 896–904, copyright (Citation1995). We acknowledge Nature Publishing Group's permission (http://www.nature.com/bjc/index.html).
Figure 4. The pharmacokinetics of SM/Chol (○), SM/Chol/PEG-DSPE (•) and SM/Chol/PEG-CER (▪) liposomal vincristine. Concentrations of liposomal lipid (A), vincristine/lipid ratio (B), concentrations of vincristine (C) in plasma at various times after intravenous administration. Reprinted from Copyright Webb et al., (Citation1998), with permission from Elsevier.
